Table of Contents

HK J Paediatr (New Series)
Vol 11. No. 1, 2006

HK J Paediatr (New Series) 2006;11:50-54

Personal Practice

Haemophilia B: Should We Stop Using Prothrombin Complex Concentrates in Hong Kong?

The Hong Kong Paediatric Haematology & Oncology Study Group: ACW Lee, MMK Shing, SC Ling, GCF Chan, HL Yuen


Abstract

The use of coagulation factor concentrates remains the mainstay treatment for haemophilias. Prothrombin complex concentrates, plasma-derived products that contain other vitamin K-dependent factors additional to factor IX, have been used for treatment of haemophilia B since 1959. However, they carry a small but significant risk of thromboembolic complications, and fatalities subsequent to myocardial infarction have been reported. We recommend that highly purified plasma-derived or recombinant products of factor IX concentrates should be the treatment of choice for patients with haemophilia B, especially those who are at higher risk for thromboembolism.

Keyword : Coagulation factor concentrate; Haemophilia B; Prothrombin complex concentrate; Thromboembolism


Abstract in Chinese

 
 

©2018 Hong Kong Journal of Paediatrics. All rights reserved. Developed and maintained by Medcom Ltd.